Shares of Accolade, Inc. (NASDAQ:ACCD – Get Free Report) have been given a consensus rating of “Moderate Buy” by the fifteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $9.04.
ACCD has been the subject of a number of research analyst reports. Barclays reduced their target price on shares of Accolade from $5.50 to $5.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 9th. Truist Financial reduced their target price on shares of Accolade from $9.00 to $7.50 and set a “buy” rating for the company in a research note on Wednesday, October 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Accolade in a research note on Monday, October 7th. Stephens reduced their target price on shares of Accolade from $10.00 to $8.00 and set an “overweight” rating for the company in a research note on Wednesday, October 9th. Finally, Wells Fargo & Company reduced their target price on shares of Accolade from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Friday, October 11th.
Get Our Latest Stock Analysis on ACCD
Institutional Inflows and Outflows
Accolade Stock Performance
Shares of Accolade stock opened at $3.21 on Friday. The firm has a fifty day moving average of $3.80 and a two-hundred day moving average of $4.96. The stock has a market capitalization of $258.53 million, a price-to-earnings ratio of -3.12 and a beta of 2.02. Accolade has a 52 week low of $3.08 and a 52 week high of $15.36. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.72 and a current ratio of 2.72.
Accolade (NASDAQ:ACCD – Get Free Report) last issued its earnings results on Tuesday, October 8th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.14. Accolade had a negative net margin of 18.16% and a negative return on equity of 18.43%. The company had revenue of $106.40 million during the quarter, compared to analysts’ expectations of $104.87 million. During the same quarter in the previous year, the company posted ($0.43) EPS. The business’s revenue for the quarter was up 9.8% compared to the same quarter last year. As a group, equities research analysts predict that Accolade will post -0.92 EPS for the current year.
Accolade Company Profile
Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.
Featured Articles
- Five stocks we like better than Accolade
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Palantir Cracks $50, Is There Still Time to Get on Board?
- How to Use the MarketBeat Dividend Calculator
- Insider Buying Signals Upside for These 3 Stocks
- Election Stocks: How Elections Affect the Stock Market
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter.